Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure

著者	Lwembe Raphael, Ochieng Washington, Panikulam Annie, Mongoina Charles O., Palakudy Tresa, Koizumi Yusuke, Kageyama Seiji, Yamamoto Naohiko, Shioda Tatsuo, Musoke Rachel, Owens Mary, Songok Elijah M., Okoth Frederick A., Ichimura Hiroshi
journal or publication title	Journal of Medical Virology
volume	79
number	7
page range	865-872
year	2007-07-01
URL	http://hdl.handle.net/2297/6599

doi: <https://doi.org/10.1002/jmv.20912>

Anti-Retroviral Drug Resistance-Associated Mutations Among Non-subtype B HIV-1-Infected Kenyan Children With Treatment Failure

Raphael Lwembe,^{1,2} Washington Ochieng,¹ Annie Panikulam,³ Charles O. Mongoina,³ Tresa Palakudy,³ Yusuke Koizumi,² Seiji Kageyama,² Naohiko Yamamoto,⁴ Tatsuo Shioda,⁵ Rachel Musoke,³ Mary Owens,³ Elijah M. Songok,¹ Frederick A. Okoth,¹ and Hiroshi Ichimura^{2*}

¹Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya

²Department of Viral Infections, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan

³Nyumbani Children's Home, Nairobi, Kenya

⁴Department of Environmental Medical Zoology, Nagoya University graduate School of Medicine, Nagoya, Japan

⁵Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

Recently increased availability of anti-retroviral therapy (ART) has mitigated HIV-1/AIDS prognoses especially in resource poor settings. The emergence of ART resistance-associated mutations from non-suppressive ART has been implicated as a major cause of ART failure. Reverse transcriptase inhibitor (RTI)-resistance mutations among 12 non-subtype B HIV-1-infected children with treatment failure were evaluated by genotypically analyzing HIV-1 strains isolated from plasma obtained between 2001 and 2004. A region of *pol-RT* gene was amplified and at least five clones per sample were analyzed. Phylogenetic analysis revealed HIV-1 subtype A1 ($n = 7$), subtype C ($n = 1$), subtype D ($n = 3$), and CRF02_AG ($n = 1$). Before treatment, 4 of 12 (33.3%) children had primary RTI-resistance mutations, K103N ($n = 3$, ages 5–7 years) and Y181C ($n = 1$, age 1 year). In one child, K103N was found as a minor population (1/5 clones) before treatment and became major (7/7 clones) 8 months after RTI treatment. In 7 of 12 children, M184V appeared with one thymidine-analogue-associated mutation (TAM) as the first mutation, while the remaining 5 children had only TAMs appearing either individually ($n = 2$), or as TAMs 1 (M41L, L210W, and T215Y) and 2 (D67N, K70R, and K219Q/E/R) appearing together ($n = 3$). These results suggest that “vertically transmitted” primary RTI-resistance mutations, K103N and Y181C, can persist over the years even in the absence of drug pressure and impact RTI treatment negatively, and that appearing patterns of RTI-resistance mutations among non-subtype B HIV-1-infected children could possibly be different from those reported in subtype B-infected children. **J. Med. Virol. 79:865–872, 2007.** © 2007 Wiley-Liss, Inc.

KEY WORDS: vertical transmission; anti-HIV resistance patterns; persistence of mutations; Kenya

INTRODUCTION

The emergence of anti-retroviral drug (ARV)-resistance mutations is a major cause of anti-retroviral treatment (ART) failure [D'Aquila et al., 1995; Lorenzi et al., 1999; Zolopa et al., 1999]. These drug-resistant HIV-1 strains can be transmitted through vertical, sexual, and parenteral routes [Erice et al., 1993; Conlon et al., 1994; Boden et al., 1999; Little et al., 1999; Brenner et al., 2000; Pillay et al., 2000; Salomon et al., 2000; Duwe et al., 2001]. Vertically transmitted multi-drug resistant HIV-1 strain has been shown to persist for 9 months in an infant after postnatal therapy [Johnson et al., 2001]. Similarly, K103N-containing HIV-1 variants acquired after the administration of single dose-nevirapine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), have been reported to persist for more than 1 year in some women and infants after vertical transmission [Flys et al., 2005]. However, long-term persistence of vertically

Grant sponsor: Japan Society for the Promotion of Science; Grant number: 14256005; Grant sponsor: Ministry of Health, Labor and Welfare, Japan.

*Correspondence to: Hiroshi Ichimura, MD, PhD, Department of Viral Infection and International Health, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa 920-8640, Japan.

E-mail: ichimura@med.kanazawa-u.ac.jp

Accepted 11 December 2006

DOI 10.1002/jmv.20912

Published online in Wiley InterScience
(www.interscience.wiley.com)

transmitted ARV-resistance mutations in the absence of drug pressure among infants and children is yet to be demonstrated.

Recently, the importance of ARV-resistant strains detected as minor populations has been reported. Minor drug-resistant HIV-1 populations have been detected both in the early phase of treatment failure [Coffin, 1995] and during successful structured treatment interruption [Metzner et al., 2003]. Minor drug-resistant populations undetectable by conventional assays can eventually overgrow and affect the clinical course [Dykes et al., 2004; Lecossier et al., 2005]. These minor drug-resistant populations have also been found to persist longer than expected previously in untreated patients, a favorable condition for wild-type virus to overgrow, which also indicates the risk of resistance transmission even from minor strains [Charpentier et al., 2004].

In patients experiencing treatment failure with nucleoside reverse-transcriptase inhibitors (NRTI), such as lamivudine plus either zidovudine or stavudine, the M184V mutation has been reported to always appear first, eventually followed by cumulative acquisition of thymidine-analogue-associated mutations (TAMs) if treatment with non-suppressive regimen is continued [Johnson et al., 2005]. Extensive studies on ARV-resistance suggest that HIV-1 may develop TAMs by either one of two distinct pathways; TAM 1 (M41L, L210W, and T215Y) or TAM 2 (D67N, K70R, and K219Q/E/N/R) [Flandre et al., 2003; Cozzi-Lepri et al., 2005]. However, most of these studies have focused on HIV-1 subtype B, which accounts for only 12% of the global HIV/AIDS pandemic, and data on non-subtype B HIV-1 is still limited. Furthermore, several differences in the development of ARV-resistance between subtype B and non-subtype B HIV-1 have been suggested [Apetrei et al., 1998; Quinones-Mateu et al., 1998; Pieniazek et al., 2000]. Most ARV-resistance studies have focused on adult populations [Yerly et al., 1998; de Ronde et al., 2001; Dykes et al., 2001; Brenner et al., 2002; Wainberg, 2003]. However, these findings may not be applicable directly to children, since several factors influencing selection of ARV-resistance such as pharmacokinetic properties; drug safety, tolerance, and antiviral activity of combination therapy, are usually different in the children [Kline et al., 1996].

The aim of this study was to investigate the patterns of emergence and the variable stability of ARV-resistance-associated mutations among non-subtype B HIV-1 vertically-infected children who developed eventually clinical failure with subsequent ART.

METHODS

Study Population

The subjects in this study resided in children's home in Nairobi, which housed 95 HIV-1-infected children. These children were born to HIV-1-infected mothers who either died of, or were too debilitated by HIV/AIDS hence could not offer basic care to the children. Of 95

children 55 were on ART as of August 2004. The duration of ART varied among children (mean: 23.3 months, range: 5–46 months). Of 55 children on ART 12 (8 males and 4 females, mean age: 7.4 years) experienced treatment failure, characterized by an initial decrease in plasma viral load (to undetectable level in one child) after treatment initiation and subsequent increase in the viral load as treatment continued. Seven of the 12 children received single ART regimen only during the study period: 5 received zidovudine/lamivudine/nevirapine, 1 zidovudine/didanosine/efavirenz, and 1 zidovudine/lamivudine/efavirenz (Table I). On the other hand, the remaining five children received multiple ART regimen during the study period: two received zidovudine/lamivudine/efavirenz followed by zidovudine/didanosine/efavirenz, two zidovudine/lamivudine/nevirapine followed by didanosine/lamivudine/efavirenz, and one didanosine/lamivudine/abacavir followed by zidovudine/didanosine/efavirenz and later didanosine/stavudine/efavirenz (Table I). These 12 children were admitted into the home by their first birthday and their HIV-1 status was confirmed serologically at 18 months of age. None of these children had history of previous exposure to any ARV.

This study was approved by the Kenya Medical Research Institute's National Ethical Review Committee on behalf of the Kenyan Government and conducted according to the national and international regulations governing the use of human subjects in biomedical research. The study was conducted within the continuing anti-retroviral, medical and healthcare programs of the institution without additional demand for blood samples solely for research purposes.

CD4⁺ Cell Counts and Plasma Viral Loads

CD4⁺ T cell counts of peripheral blood were determined using the FACSCOUNT (Becton-Dickinson, Beiersdorf, Germany) and plasma HIV-1 RNA loads using the Amplicor HIV-1 Monitor kit version 1.5 (Roche Diagnostics, Alameda, CA) with detection limit of 400 copies/ml according to the manufacturer's instructions.

Extraction and Amplification of Plasma HIV-1 Viral RNA

HIV-1 RNA was extracted from 100 µl of plasma using SMITEST EX-R and D (Sumitomo Metal Industries, Tokyo, Japan) according to the manufacturer's instructions. A region of the *pol-RT* gene (corresponding to nt 2480–3180 of HIV-1_{HXB2}) was amplified by both one-step RT-PCR (Invitrogen, Carlsbad, CA) and nested PCR with primer pairs, RT18 (5'-GGAAACCAAAAATGATAGGGGGAATTGGAGG-3') and KS104 (5'-TGAC-TTGCCCAATTTAGTTTTCCCACTAA-3') in the first round, and KS101 (5'-GTAGGACCTACACCTGTTC-AACATAATTGGAAG-3') and KS102 (5'-CCCATCCAAAGAAATGGAGGAGGTTCTTTCTGATG-3') in the second round [Ndambi et al., 2004; Songok et al.,

TABLE I. General Characteristics of Non-B Subtype HIV-1-Infected Study Children

Sample ID	Age* (years)/sex	HIV-1 subtype/CRF	Study point (month, year)	ART ^a (initiation time)	CD4 ⁺ T cell count (/μl)	Plasma viral load (copies/ml)	NRTT ^b -resistance mutations	NNRTT ^c -resistance mutations
NYU30	11/F	A1	Jul '02 Mar '03 Jan '04	ZDV, 3TC, EFV (Jun '01) ZDV, DDI, EFV (May '03)	456 475 267	<400 24,857 89,063	D67N + K70R + K219Q	L100I
NYU33	11/F	A1	Jul '02 Mar '03 Feb '04	ZDV, 3TC, EFV (Jun '01) ZDV, DDI, EFV (Oct '01)	549 556 690	3,449 122,419 6,457	K219Q K219Q + D218E	K101Q K101Q
NYU36	11/M	D	Oct '01 May '02 Aug '02 Apr '03 Feb '04	ddI, 3TC, ABC (Apr '01) ZDV, DDI, EFV (Oct '01) D4T, DDI, EFV (Nov '02)	309 321 279 458	114,754 880,405 81,870 607,224 393,420	M184V + T215F M184V + T215F M184V + T215F T215F T215F	I178M G190A G190A G190A
NYU38	10/M	C	Mar '03 Dec '03	ZDV, 3TC, NVP (Sep '02)	388 188	38,459 60,695	D67N D67N + K70R + L210W + K219E	
			Feb '04	DDI, 3TC, EFV (Mar '04)	157	38,211	D67N + K70R + L210W + K219E	
			Aug '04		149		D67N + K70R + L210W + K219E	
NYU44	9/M	A1	Feb '02 Mar '03 Dec '03	ZDV, DDI, EFV (May '02)	208 370 474	1,017,931 71,895 150,549	D67N + K70R + T215F + K219Q D67N + K70R + T215F + K219Q + M41L + V75M	K103N K103N + G190A K103N + G190A
NYU62	8/M	A1	Dec '01 Sep '02 Mar '03 May '04	ZDV, 3TC, NVP (Sep '02)	589 828 568	239,644 2,838	D67N + K70R D67N + K70R + T215F + K219E D67N + K70R + T215F + K219E	G190A G190A G190A + Y181C
NYU69	6/M	A1	Mar '03 May '04	ZDV, 3TC, NVP (Mar '03)	192 400	227,176 113,868	M184V	K103N K103N
NYU70	7/M	D	Sep '02 Jun '03 Dec '03	ZDV, 3TC, NVP (Jul '03)	718 169 502	700,563 1,323,431 188,059	K70R + M184V	K103N K103N K103N
NYU79	6/M	A1	Feb '03 Feb '04 Jun '04	ZDV, 3TC, NVP (Apr '03) DdI, 3TC, EFV (Mar '04)	70 551 347	159,826 244,506 472,203	V75M + M184V V75M + M184V	K101E + G190A K101E + G190A + Y181C
NYU83	5/M	A1	May '01 Jul '02 Apr '03 Aug '04	ZDV, 3TC, EFV (May '04)	876 946 1138 1125	634,644 50,570 74,437 197,301	M184V M184V M184V + T215Y	K103N K103N K103N
NYU85	5/F	CRF02_AG	Feb '03 Dec '03 Apr '04	ZDV, 3TC, NVP (Apr '03)	178 1214 1148	30,690 3,264 79,080	D67N + M184V D67N + M184V	K103N K103N
NYU90	2/F	D	Apr '03 Jan '04 Mar '04	ZDV, 3TC, NVP (Apr '03)	6 399 379	523,950 55,679 155,191	M184V	Y181C K103N

*As of August 2004.

^aART, anti-retroviral therapy; ZDV, zidovudine; ddI, didanosine; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; d4T, Stavudine.^bNRTI, nucleoside analogue RTI.^cNNRTI, non-nucleoside RTI; blank, no mutation detected.

2004]. Amplification was done with 1 cycle of 95°C for 10 min and 35 cycles of 95°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min, with a final extension of 72°C for 10 min. PCR amplification was confirmed by ethidium bromide staining of samples electrophoresed on an agarose gel.

Cloning, Sequencing, and Subtyping

The amplified products were cloned using the TOPO TA Cloning kit (Invitrogen) and sequenced as described previously [Ndembu et al., 2004; Songok et al., 2004]. The sample nucleotide sequences were aligned with HIV-1 subtype reference sequences from the Los Alamos database by CLUSTALW (version 1.81) with minor manual adjustments. Phylogenetic trees were constructed and visualized as described previously [Ndembu et al., 2004; Songok et al., 2004]. To improve the accuracy of HIV-1 subtyping, we used the genotyping tool (<http://www.ncbi.nih.gov/projects/genotyping/formpage.cgi>), and the REGA subtyping tool (<http://dbpartners.stanford.edu/RegaSubtyping/>) as needed.

RTI Resistance-Associated Mutations

The RT nucleotide sequences (697 bps) were translated into the corresponding 232 amino acids and analyzed for previously reported drug resistance-associated mutations in subtype B strains using the Stanford university HIVdb sequence analysis program. For each sample, at least five clones were obtained and genotyped to detect the presence of minor populations.

RESULTS

General characteristics, treatment history, demographic, immunological, and virological data of the 12 HIV-1-infected children studied are summarized in Table I.

HIV-1 Subtypes

All children were infected with non-subtype B HIV-1: subtype A1 (n = 7), subtype C (n = 1), subtype D (n = 3), and circulating recombinant form (CRF)-02_AG (n = 1) (Table I).

RTI Resistance-Associated Mutations Before Treatment

Of the 12 children, 4 (33.3%) harbored NNRTI-resistance mutations before treatment. Three children, NYU44 (age, 7 years), NYU69 (5 years), and NYU70 (6 years), had K103N while NYU90 (1 year) had Y181C detected before treatment (Table I). All the mutations but one (one of seven clones in NYU69) were detected as full clones (Table IV). K103N detected in three children persisted, while Y181C detected in one child disappeared during treatment.

Emerging Pattern of NRTI Resistance-Associated Mutations

The patterns of NRTI-resistance mutations are summarized in Table II. M184V appeared as the first

TABLE II. Patterns of NRTI*-Resistance Mutations in Non-B Subtype HIV-1-Infected Children With Treatment

Child (ID)	Study point (mpti ^a)					Treatment
	1st	2nd	3rd	4th	5th	
NYU69	M184V (10)					ZDV/3TC
NYU90	M184V (9)					ZDV/3TC
NYU83	M184V (13)					ZDV/3TC
NYU70	M184V + 1TAM (6)	M184V (22)	M184V + 1TAM ^b (38)			ZDV/3TC
NYU85	M184V + 1TAM (9)	M184V + 1TAM (12)				ZDV/3TC
NYU36	M184V + 1TAM (6)	M184V + 1TAM (13)				DDI/3TC/ABC, ZDV/DDI, D4T/DDI
NYU62	2 TAMs (6)	4 TAMs (12)	M184V + 1TAM (18)	1 TAM (24)	1 TAM (34)	ZDV/3TC
NYU44	4 TAMs (11)	5 TAMs + V75M (19)	4 TAMs (22)			ZDV/DDI
NYU33		1 TAM (23)				ZDV/3TC, ZDV/DDI
NYU30			2 TAMs (34)			ZDV/DDI
NYU38	1 TAM (8)	4 TAMs (15)	3 TAMs (31)			ZDV/3TC, DDI/3TC
NYU79	M184V + V75M (10)	M184V + V75M (13)	4 TAMs (17)	5 TAMs (23)		ZDV/3TC, DDI/3TC

*NRTI, nucleoside analogue RTI.

^ampti, months post treatment initiation.

^bTAM, thymidine analogue-associated resistance mutation; blank, no mutation detected.

primary NRTI-resistance mutation in 3 of 12 children (NYU69, NYU90, and NYU83), (later followed by the acquisition of one TAM in NYU83), while M184V appeared as first primary NRTI-resistance mutation with one TAM in three children (NYU36, NYU70, and NYU85) who received zidovudine/lamivudine, zidovudine/didanosine, or lamivudine/didanosine. The remaining five children (NYU30, NYU33, NYU38, NYU44, and NYU62) had a mixture of TAMs appearing as first mutations. Three of them (NYU44, NYU62, and NYU38) had both TAM 1 (M41L, L210W, and T215Y) and TAM 2 (D67N, K70R, and K219Q) profiles detected together. M184V appeared as the first primary NRTI-resistance mutation together with V75M in child NYU79. NYU33 developed K219Q only, a “secondary” NRTI-resistance mutation.

Emerging Pattern of NNRTI Resistance-Associated Mutations

In four of the five children who received nevirapine (NYU69, NYU70, NYU85, NYU90) K103N appeared as the first primary NNRTI-resistance mutation, while in one (NYU62) G190A appeared as the first mutation (Table III). In two of the five children who received efavirenz (NYU44 and NYU 83) K103N appeared as the first NNRTI-resistance mutation, while in two children (NYU30 and NYU33) L100I and K101Q, respectively, appeared as the first NNRTI-resistance mutation. One child (NYU36) who received didanosine/lamivudine/abacavir with subsequent change to an efavirenz-containing regimen developed I178M as the first NNRTI-resistance mutation, which was replaced later by appearance of G190A.

One child (NYU79) developed K101E and G190A as first NNRTI-resistance mutations with nevirapine therapy and developed additionally Y181C when ART was changed to efavirenz-containing regimen during the study period.

In the remaining one child (NYU38) no known NNRTI-resistance mutation was detected despite receiving nevirapine—and later efavirenz-containing regimen (Table III).

Growth of Minor Mutant Virus Population into Major One

Five of 12 children had RTI-resistance mutations detected as minor virus populations, which subsequently grew into full clones (Table IV). In the remaining seven children no RTI-resistant mutation was detected as a minor population (data not shown).

RTI-resistance mutations, such as T215F in child NYU36, T215F in NYU44, D67N/K70R/T215F in NYU62, and K101Q/K219Q in NYU33, appeared as minor populations after initiation of treatment, which overgrew subsequently to major populations.

In one child (NYU69), K103N was found as a minor population (1/5 clones) before initiation of treatment and became major population (7/7 clones) 8 months after treatment.

TABLE III. Patterns of NNRTI^a-Resistance Mutations Among Non-B Subtype HIV-1-Infected Children With Treatment

Child (ID)	Pre-treatment	Study point (mpti ^a)					Treatment
		1st	2nd	3rd	4th	5th	
NYU69	K103N (-4)	K103N (10)					NEVIRAPINE
NYU70	K103N (-10, -1)	K103N (11)					
NYU85		K103N (9)					
NYU62		G190A (6)	K103N (12)	G190A + Y181C (26)			
NYU90	Y181C (-0.25)		G190A (12)				
NYU38			K103N (11)				EFAVIRENZ
NYU83		K103N (12)		K103N (38)			
NYU30				L100I (31)			
NYU44		K103N + G190A (10)	K103N + G190A (18)				
NYU33	K103N (-3)		K101Q (11)	K101Q (34)			
NYU36			I178M (13)	G190A (16)			
NYU79		K101E + G190A (10)	K101E + G190A + Y181C (14)		G190A (24)	G190A (34)	
NYU38							

NNRTI: non-nucleoside analogue RTI.
^ampti, months post treatment initiation; blank, no mutation detected.

TABLE IV. Evolution of Minor RTI-Resistance Mutant Populations Among Non-B HIV-1-Infected Children With Treatment

Child ID	Study point (months post treatment)	ART ^a	Plasma viral load (copies/ml)	NR ^b resistance mutations	NNRTI ^c -resistance mutations
NYU36	1st (6)		114,754	T215F (1/9)^d + M184V (6/8)	
	2nd (13)	DDI, 3TC, ABC	880,405	T215F (1/8) + M184V (2/8)	I178M (6/8)
	3rd (18)	ZDV, DDI, EFV	81,870	T215F (9/9) + M184V (8/9)	G190A (8/9)
	4th (24)		607,224	T215F (5/5)	G190A (5/5)
	5th (34)	D4T, DDI, EFV	393,420	T215F (7/7)	G190A (7/7)
NYU44	Pre-treatment		1,017,931		K103N (5/5)
	1st (10)	ZDV, DDI, EFV	71,895	D67N (5/5) + K70R (5/5) + T215F (1/5) + K219Q (5/5)	K103N (5/5) + G190A (5/5)
	2nd (17)		150,549	+ M41L (1/5) + V75M (3/5)	K103N (5/5) + G190A (5/5)
NYU62	Pre-treatment		239,644		
	1st (6)		2,838	D67N (1/5) + K70R (1/5)	G190A (5/5)
	2nd (12)	ZDV, 3TC, NVP		D67N (5/5) + K70R (5/5) + T215F (2/5) + K219E (5/5)	G190A (5/5)
NYU69	3rd (26)		6,901	D67N (5/5) + K70R (5/5) + T215F (2/5) + K219E (5/5)	Y181C (4/5) + G190A (5/5)
	Pre-treatment		227,176		K103N (1/5)
	1st (10)	ZDV, 3TC, NVP	113,868	M184V (7/7)	K103N (7/7)
NYU33	1st (15)		3,449		
	2nd (23)	ZDV, 3TC, EFV	122,419	K219Q (4/11)	K101Q (6/11)
	3rd (34)	ZDV, DDI, EFV	6,457	K219Q (14/14) + D218E (14/14)	K101Q (14/14)

^aART, anti-retroviral therapy; ZDV, zidovudine; ddI, didanosine; EFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; d4T, Stavudine.^bNR^b, nucleoside analogue RTI.^cNNRTI, non-nucleoside RTI, blank: no mutation detected.^dNumber of clones with mutation/ total number of clones analysed; bold, minor RTI-resistant mutant populations that evolved.

DISCUSSION

In the current study, NNRTI resistance-associated primary mutations, K103N and Y181C, were found before ART in four (33.3%) of 12 HIV-1-vertically-infected Kenyan children with subsequent ART failure. Three children aged 5–7 years already had K103N mutation, while one child aged 1 year already had Y181C by the time ART was started. These children had no history of previous exposure to any ART or blood transfusion, suggesting that these drug-resistance mutations were transmitted vertically from their mothers. However, ART history of these children's mothers could not be confirmed, and the use of nevirapine to reduce transmission of HIV-1 from mother to child had not been started by the year 2002 in Kenya [NASCOP, 2002].

This is the first report on the long-term persistence of NNRTI-resistance mutation for upto 7 years in vertically HIV-1-infected children albeit in the absence of ART. The K103N mutation has been reported to have little impact on the replicative capacity of HIV-1, allowing K103N variants to persist as dominant species at the expense of the wild strains [Brenner et al., 2002]. Thus, these current findings emphasize the need for drug-resistance testing among HIV-1-infected children prior to starting any NNRTI-containing regimen to avoid earlier treatment failure.

The selection of some ARV-resistance mutations among minor HIV-1 populations after ART initiation has been reported previously [Coffin, 1995; Metzner et al., 2003; Charpentier et al., 2004; Dykes et al., 2004; Lecossier et al., 2005]. In this study, RTI-resistance mutations detected in five children as minor populations after ART initiation subsequently grew into major populations, resulting in ART failure. In addition, it is noted that a primary NNRTI-resistance mutation, K103N, was found in one of five HIV-1 clones from a drug-naïve Kenyan child (NYU69), and this minor drug-resistant virus became dominant (seven of seven clones) after 8-months ART, resulting in treatment failure. These findings indicate that minor ARV-resistant HIV-1 variants existing before therapy can also be an important cause of treatment failure, as suggested previously [Dykes et al., 2004; Lecossier et al., 2005; Johnson et al., 2006]. Standard genotyping methods can only detect more than 25% of the virus variants [Gunthard et al., 1998]. Therefore, in order to pick minor variant populations and pre-empt treatment failure, more sensitive detection methods for minor HIV-1 populations would be required [Edelstein et al., 1998; Gunthard et al., 1998; Grant et al., 2002; Schuurman et al., 2002; Malet et al., 2003; Shi et al., 2004; Palmer et al., 2005].

Results from this study suggest the possible existence of two different patterns of emergence or acquisition of the TAMs among children who receive thymidine-analogues such as zidovudine, lamivudine, and/or stavudine. Seven of the 12 children had an initial development of M184V mutation, followed by the cumulative acquisition of TAMs, consistent with previous studies of subtype

B HIV-1 [Johnson et al., 2005], which reported that TAMs always develop by either one of two distinct pathways, TAM1 (M41L, L210W, and T215Y) or TAM 2 (D67N, K70R, and K219Q/E/R), under the pressure of thymidine analogue-containing ARVs. The remaining five children, however, developed TAMs only without the initial appearance of M184V mutation. Additionally, three of these children developed both TAMs 1 and 2 members concurrently, discordant with previous reports [Flandre et al., 2003; Cozzi-Lepri et al., 2005]. One child (NYU33) developed K219Q and K101Q mutations only, after 2-year treatment with zidovudine, didanosine, and efavirenz. These two mutations have been previously grouped among the secondary RTI-resistance-associated mutations, unable to cause drug-resistance in the absence of other primary RTI-resistance-associated mutations such as K70R or T215F [Garcia-Lerma, 2005]. These findings therefore suggest the possible existence of different pathways for development of RTI-resistance in non-subtype B HIV-1-infected children, different from those reported in subtype B-infected individuals, and that secondary RTI-resistance-associated mutations namely K219Q and K101Q could independently cause ART resistance among non-subtype B HIV-1-infected children. Further studies are however needed in order to confirm these findings.

The K103N mutation has been reported as the most commonly selected NNRTI-resistance-associated mutation, usually appearing first [Johnson et al., 2005]. The results from the children who received nevirapine in this study agree with this observation. However, the children who received efavirenz developed a variety of NNRTI-resistance-associated mutations, such as L100I, K101Q, I178M, and G190A. This is the first report to show the possibility of the K101Q and I178M to appear as the first NNRTI-resistance mutations with efavirenz therapy. L100I, Y181C, and G190A have already been described [Johnson et al., 2005]. In addition, one child (NYU38) who received nevirapine and later efavirenz containing regimen did not have any NNRTI-resistance-associated mutation despite experiencing treatment failure, suggesting a possible difference in the initial selection of NNRTI-resistant mutations between non-subtype B and subtype B HIV-1-infected children. However, considering recent reports on the association between a homozygous variant of multidrug-resistance transporter *C3435T* and good immune recovery [Saitoh et al., 2005], and the correlation of homozygous *CYP2B6* *6 with plasma efavirenz concentrations in HIV-1-infected individuals treated with efavirenz-containing regimen [Tsuchiya et al., 2004], further pharmacogenetic studies would also be needed to elucidate these phenomenon.

In conclusion, this study suggests a possible long-term persistence of "vertically transmitted" NNRTI-resistance mutations in the absence of drug pressure, that minor populations of RTI-resistant HIV-1 mutants may impact negatively on the outcome of ART, and that there is a possible difference in the pattern of appearance and profile of RTI-resistance mutations between non-

subtype B and subtype B HIV-1-infected children. Further studies with large population size are needed to confirm these findings.

SEQUENCE DATA

GenBank accession numbers of the sequences reported in this study are DQ679541 to DQ679753 for *Pol-RT*.

ACKNOWLEDGMENTS

The authors are grateful to the children who joined this study. Without their contribution this work would not have been possible. The authors also wish to thank Dr. Davy Koech, the Director of Kenya Medical Research Institute (KEMRI), whose facilitation ensured the successful completion of the study. This work was supported in part by Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research, grants 14256005) and the Ministry of Health, Labor and Welfare, Japan. This work is published with the permission of the Director, KEMRI.

REFERENCES

- Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F, Brun-Vezinet F. 1998. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. *J Virol* 72:3534–3538.
- Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M. 1999. HIV-1 drug resistance in newly infected individuals. *JAMA* 282:1135–1141.
- Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, Sekaly RP, Conway B, Routy JP. 2000. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. *Int J Antimicrob Agents* 16:429–434.
- Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Dettori M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. 2002. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. *J Virol* 76:1753–1761.
- Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. *J Virol* 78:4234–4247.
- Coffin JM. 1995. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. *Science* 267:483–489.
- Conlon CP, Klenerman P, Edwards A, Larder BA, Phillips RE. 1994. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. *J Infect Dis* 169:411–415.
- Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD, EuroSIDA Study Group. 2005. Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy. *Antivir Ther* 10:791–802.
- D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. *Ann Int Med* 122:401–408.
- de Ronde A, van Dooren M, van Der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J. 2001. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. *J Virol* 75:595–602.
- Duwe S, Brunn M, Altmann D, Hamouda O, Schmidt B, Walter H, Pauli G, Kucherer C. 2001. Frequency of genotypic and phenotypic

- drug-resistant HIV-1 among therapy-naïve patients of the German Seroconverter Study. *J Acquir Immune Defic Syndr* 26:266–273.
- Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. *Virology* 285:193–203.
- Dykes C, Najjar J, Bosch RJ, Wantman M, Furtado M, Hart S, Hammer SM, Demeter LM. 2004. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. *J Infect Dis* 189:1091–1096.
- Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. 1998. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. *J Clin Microbiol* 36:569–572.
- Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, Balfour HH Jr. 1993. Brief report: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. *N Engl J Med* 328:1163–1165.
- Flandre P, Descamps D, Joly V, Meiffredy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vezinet F. 2003. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received. *Antivir Ther* 8:65–72.
- Flys T, Nissley DV, Claassen CW, Jones D, Shi C, Guay LA, Musoke P, Mmro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. *J Infect Dis* 192:24–29.
- Garcia-Lerma JG. 2005. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons. *J Antimicrob Chemother* 56:265–269.
- Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. *JAMA* 288:181–188.
- Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD. 1998. Comparative performance of high-density oligonucleotide and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. *AIDS Res Hum Retroviruses* 14:869–876.
- Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. 2001. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. *J Infect Dis* 183:1688–1693.
- Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. 2005. Update of the drug resistance mutations in HIV-1:2005. *Top HIV Med* 13:51–57.
- Johnson JA, Li J-F, Wei X, Craig C, Stone C, Horton JH, Lanier ER, Heneine W. 2006. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral naïve HIV-infected persons. *Anti Therapy* 11:S79.
- Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM. 1996. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: Pharmacokinetic properties, safety, and immunologic and virologic effects. *Pediatrics* 97:886–890.
- Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, Hance AJ. 2005. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. *J Acquir Immune Defic Syndr* 38:37–42.
- Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. *JAMA* 282:1142–1149.
- Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S. 1999. Impact of drug resistance mutations on virologic response to salvage therapy. *AIDS* 13:F17–F21.
- Malet I, Belnard M, Agut H, Cahour A. 2003. From RNA to quasiespecies: A DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. *J Virol Methods* 109:161–170.
- Metzner KJ, Bonhoeffer S, Fischer M, Karanickolas R, Allers K, Joos B, Weber R, Hirschel B, Kostrikis LG, Gunthard HF, The Swiss HIV Cohort Study. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. *J Infect Dis* 188:1433–1443.
- NASCOP. 2002. National Guidelines: Prevention of mother to child HIV/AIDS transmission 2nd edition.
- Ndembi N, Takehisa J, Zekeng L, Kobayashi E, Ngansop C, Songok EM, Kageyama S, Takemura T, Ido E, Hayami M, Kaptue L, Ichimura H. 2004. Genetic diversity of HIV type 1 in rural eastern Cameroon. *J Acquir Immune Defic Syndr* 37:1641–1650.
- Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT Jr, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. 2005. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. *J Clin Microbiol* 43:406–413.
- Pieniazek D, Rayfield M, Hu DJ, Nkengasong J, Wiktor SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A, Soriano V, Lal R, Dondero T. 2000. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide. HIV Variant Working Group. *AIDS* 14:1489–1495.
- Pillay D, Cane PA, Shirley J, Porter K. 2000. Detection of drug resistance associated mutations in HIV primary infection within the UK. *AIDS* 14:906–908.
- Quinones-Mateu ME, Albright JL, Mas A, Soriano V, Arts EJ. 1998. Analysis of pol gene heterogeneity, viral quasiespecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. *J Virol* 72:9002–9015.
- Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. 2005. An MDR-1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. *AIDS* 19:371–380.
- Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP. 2000. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. *AIDS* 14:F17–F23.
- Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA, ENVA Working Group. 2002. Underestimation of HIV type 1 drug resistance mutations: Results from the ENVA-2 genotyping proficiency program. *AIDS Res Hum Retroviruses* 18:243–248.
- Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman JR. 2004. LigAmp for sensitive detection of single-nucleotide differences. *Nat Methods* 1:141–147.
- Songok EM, Lwembe RM, Kibaya R, Kobayashi K, Ndembi N, Kita K, Vulule J, Oishi I, Okoth F, Kageyama S, Ichimura H. 2004. Active generation and selection for HIV intersubtype A/D recombinant forms in a coinfecting patient in Kenya. *AIDS Res Hum Retroviruses* 20:255–258.
- Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. 2004. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. *Biochem Biophys Res Commun* 319:1322–1326.
- Wainberg MA. 2003. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 34:S2–S7.
- Yerly S, Rakik A, De Loes SK, Hirschel B, Descamps D, Brun-Vezinet F, Perrin L. 1998. Switch to unusual amino acids at codon 215 of human immunodeficiency virus type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants. *J Virol* 72:3520–3523.
- Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. *Ann Intern Med* 131:813–821.